Navigation Links
Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
Date:12/4/2012

SAN DIEGO, Dec. 4, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will provide details of obesity therapeutics market research including the results of surveys of 1,000 physicians and 6,000 patients during an Analyst Day event on December 18, 2012. The Company will also provide an update to the Contrave® Light Study and discuss U.S. and EU regulatory planning.

The Analyst Day event will be held in New York City on December 18, 2012 from 9 a.m. to 12 p.m. Eastern Time.

While attendance in person is by invitation only, Orexigen will webcast the Analyst Day presentations. The webcast can be accessed live on the Investor Relations section of the Orexigen website at www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.
 

Source:
Orexigen Therapeutics
McDavid Stilwell
Vice President, Corporate Communications & Business Development
858-875-8600


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
2. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
3. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
4. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
7. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
8. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
9. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
10. Flexion Therapeutics Secures $20 Million in Series B Financing
11. Echo Therapeutics Announces Proposed Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Mass. , March 22, 2017  Applied ... mechanistic modeling to drug research and development, today ... Day 2017.  QSP Day 2017 is a day ... the quantitative systems pharmacology (QSP) community. The focus ... modeling is de-risking and accelerating drug research and ...
(Date:3/22/2017)... March 22, 2017 Hologic, Inc. (Nasdaq: ... the acquisition of Cynosure, Inc., a leader in medical ... cash. "We are pleased to complete our ... Michael Davin and the entire Cynosure team ... growing medical aesthetics market," said Steve MacMillan , ...
(Date:3/22/2017)... YORK , March 22, 2017 ... (EP) market is growing rapidly due to the significant ... report published by Allied Market Research, the global electrophysiology ... expected to reach $8.271 billion by 2022, with a ... and is used to diagnose abnormal heartbeats or arrhythmia. ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... An intensive search of the medical literature has ... Norins, MD, PhD. He says investigating this possibility, is important because Miami-Dade ... in new infections with HIV. , His findings appear on Analizir.com. ...
(Date:3/22/2017)... MA San Antonio, TX (PRWEB) , ... March ... ... and ISO certified medical imaging core lab with extensive therapeutic experience and operational ... a multi-year phase II immuno-oncology clinical trial for the treatment of non-small cell ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Jim ... regional families and business owners, is joining the Teen Recovery Solutions organization in ... area. , A growing number of Oklahoma teens and adolescents face problems from ...
(Date:3/22/2017)... ... 22, 2017 , ... College basketball surges to its peak during the March ... that is, recruiting people to be foster parents. Through a televised spot, Coach Self ... foster care due to abuse, neglect and other family challenges. People who respond to ...
(Date:3/22/2017)... ... ... Nearly a decade after it was first recommended that men over the ... to stir controversy. The US Preventative Services Task Force (USPSTF) issued a recommendation against ... news from a study published in JAMA Oncology suggests that more men ...
Breaking Medicine News(10 mins):